Treatment That Can Be Given in a Short Period of Time and Produce a Durable Response Would Lead to Better Safety for the Patients with MS

At ACTRIMS 2025, the current President of the ACTRIMS organization and Professor of Neurology at the University of Ottawa, Canada, presented accumulated real-world evidence on the use of high-efficacy therapies in Multiple Sclerosis. The data reinforces the importance of initiating high-efficacy treatment early in the disease course to optimize long-term outcomes. However, to enhance patient safety, neurologists must develop a deeper understanding of the pharmacological profiles, risk-benefit ratios, and individualized treatment considerations for each high-efficacy therapy.